Skip to main content
ConductScienceScienceDex

Ferdinandos Skoulidis

NIH Rank #6920
Unclaimed recordClaim profile
  • R01 Holder
  • Early Career

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 15708312Search this ID in NIH RePORTER
ScienceDex PI coverage
FY2024 through FY2026Career claims are limited to the years shown.

FY2026 award categories

  • Internal Medicine

NIH Funding · FY2024

Linked Award Amount
$1.7M
Full award amounts, FY2024
Award Records
4
Records listing this PI
Award-Linked Rank
#6,920
By linked amount among FY2024 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Ferdinandos Skoulidis. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2024 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2024 award records by amount

NIH award records listing Ferdinandos Skoulidis as a PI. Multi-PI records show the full award amount for context.

  • 1R01CA279452-01A1R01
    Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor
    UT MD Anderson Cancer Center
    $672.3K
    award amount
  • 5R01CA272570-02R01
    Dissecting and targeting mechanisms of genomic instability-triggered immune evasion in RBM10-deficient non-small cell lung cancer
    UT MD Anderson Cancer Center
    $352K
    award amount
  • 5R01CA279194-02R01
    Dissecting and targeting tumor-TME crosstalk to forestall acquired KRASG12C inhibitor resistance in NSCLC.
    UT MD Anderson Cancer Center
    $352K
    award amount
  • 5R01CA262469-04R01
    Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancer
    UT MD Anderson Cancer Center
    $352K
    award amount

Award organization

Organizations that administered FY2024 awards listing Ferdinandos Skoulidis as a PI.

FY2024 award administered by UT MD Anderson Cancer Center (TX).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2024
    First NIH Award
    UT MD Anderson Cancer Center
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2024
    Entered Top 50% Nationally
    Ranked #6920
  5. 2025
    $2M Cumulative Funding
  6. 2025
    R01 Grant Holder

Shared-award investigators

Other investigators listed on at least one of the same NIH award records as Ferdinandos Skoulidis.

David John Tweardy
UT MD Anderson Cancer Center
2
shared awards
Seyed Javad Mirhassani Moghaddam
UT MD Anderson Cancer Center
2
shared awards
Humam Kadara
UT MD Anderson Cancer Center
1
shared award

Explore further

Find collaborators for Ferdinandos Skoulidis

Search NIH-funded principal investigators by topic, department, or activity.

Open Find Collaborators →

Benchmark grant budgets

Compare median NIH grant budgets across departments, mechanisms, and years.

Open Grant Budget Benchmark →